Jazz Pharmaceuticals JAZZ Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Free cash flow margin | 30.4%-3.0pp | 33.4%+5.5pp | 27.9%-6.1pp | 34%+9.7pp | |
| Efficiency | |||||
| Asset turnover | 0.4×0.0× | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | |
| Liquidity | |||||
| Current ratio | 1.9×-2.6× | 4.5×+2.2× | 2.2×-0.6× | 2.8×-0.4× | |
| Quick ratio | 1.7×-2.3× | 4×+2.1× | 1.8×-0.2× | 2×+0.1× | |
| Cash ratio | 0.3×-2.0× | 2.3×+1.3× | 1×0.0× | 0.9×+0.2× | |
| Leverage | |||||
| Debt-to-equity | 1.3×-0.2× | 1.5×0.0× | 1.6×-0.3× | 1.9×+0.3× | |
| Debt-to-assets | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | |
| Per Share | |||||
| Book value per share | $70.82+14.2% | $62.02+19.6% | $51.86+5.1% | $49.34-25.7% | |
| Valuation | |||||
| Market capitalization | $10.33B+38.8% | $7.44B-3.3% | $7.7B-23.3% | $10.03B+28.1% | |
| Enterprise value | $15.07B+34.6% | $11.2B-6.6% | $11.99B-19.9% | $14.97B+11.7% | |
| Price / sales | 2.4×+0.6× | 1.8×-0.2× | 2×-0.7× | 2.7×+0.2× | |
| Price / book | 2.4×+0.6× | 1.8×-0.2× | 2.1×-1.2× | 3.3×+1.3× | |
| EV / sales | 3.5×+0.8× | 2.8×-0.4× | 3.1×-1.0× | 4.1×-0.2× | |
| Free cash flow yield | 12.6%-5.7pp | 18.2%+4.4pp | 13.9%+1.5pp | 12.4%+2.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Jazz Pharmaceuticals's ratios come from?
- Every ratio is computed from Jazz Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
